Ventana PD-L1 (SP142) assay approved as CDx for TNBC

Create PDF

Launched in 2016, the Ventana PD-L1 (SP142) Assay is the primary diagnostic assay within the Tecentriq clinical development program and was used to enroll and stratify patients in Tecentriq clinical trials. The assay was the first to evaluate patient PD-L1 biomarker status using immune cell staining and scoring within the tumor microenvironment.